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ABSTRACT:
Adiponectin is an adipokine that can suppress the proliferation of various human 
carcinoma cells. Although its anti-tumor activities have been suggested by many 
clinical investigations and animal studies, the underlying mechanisms are not fully 
characterized. In MMTV-polyomavirus middle T antigen (MMTV-PyVT) transgenic mice 
models, reduced- or complete loss-of-adiponectin expression promotes mammary 
tumor development. The present study demonstrated that while tumor development 
in control MMTV-PyVT mice is associated with a progressively decreased circulating 
cholesterol concentration, adiponectin deficient MMTV-PyVT mice showed significantly 
elevated total- and low density lipoprotein (LDL)-cholesterol levels. Cholesterol 
contents in tumors derived from adiponectin deficient mice were dramatically 
augmented. High fat high cholesterol diet further accelerated the tumor development 
in adiponectin deficient PyVT mice. The protein levels of LDL receptor (LDLR) were 
found to be upregulated in adiponectin-deficient tumor cells. In human breast 
carcinoma cells, treatment with LDL-cholesterol or overexpressing LDLR elevates 
nuclear beta-catenin activity and facilitates tumor cell proliferation. On the other 
hand, adiponectin decreased LDLR protein expression in breast cancer cells and 
inhibited LDL-cholesterol-induced tumor cell proliferation. Both in vivo and in vitro 
evidence demonstrated a stimulatory effect of adiponectin on autophagy process, 
which mediated the down-regulation of LDLR. Adiponectin-induced reduction of LDLR 
was blocked by treatment with a specific inhibitor of autophagy, 3-methyladenine. In 
conclusion, the study demonstrates that adiponectin elicits tumor suppressive effects 
by modulating cholesterol homeostasis and LDLR expression in breast cancer cells, 
which is at least in part attributed to its role in promoting autophagic flux. 
INTRODUCTION
The relationship between dysregulated metabolism 
and carcinogenesis was first enunciated by Otto Warburg 
more than 80 years ago [1]. There is now a large body 
of evidence supporting a link between obesity, metabolic 
syndrome, insulin resistance with increased risk of cancers 
[2-4]. For example, overweight and obesity account for 
over 25% of the patients with breast cancer, the most 
frequent cancer and the second leading cause of cancer 
death among women [5, 6]. Excess adiposity is associated 
with late-stage disease and poor prognosis in breast cancer. 
On the other hand, information is limited on the detailed 
molecular links between aberrant metabolism in obesity 
and elevated cancer risks.
Adipokines are a family of molecules selectively 
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secreted by fat tissue. Evidence from clinical, 
epidemiological and experimental studies suggests that 
adipokines are key pathological mediators in obesity-
related cancer diseases [7-9]. Under obese condition, 
adipose tissue becomes “inflamed” to produce excess 
amount of inflammatory adipokines, such as tumor 
necrosis factor alpha (TNFα), leptin and lipocalin-2, 
which promote breast cancer cell survival, proliferation 
and tumor development [3, 10]. On the other hand, the 
circulating level of adiponectin, the anti-inflammatory 
adipokine, is inversely associated with obesity-related 
cancer diseases [11, 12]. Low serum adiponectin levels 
in obese women are associated with an increased risk for 
breast cancer development and mortality [13, 14]. Women 
with higher adiponectin levels have a reduced risk of 
breast cancer [14, 15]. Moreover, tumors in women with 
the low serum adiponectin levels are more likely to show 
a biologically aggressive phenotype with poor prognosis 
[16, 17]. Numerous experimental studies have shown the 
anti-proliferative activity of adiponectin in breast cancer 
cells and animal models [11, 18-22]. 
In mouse models with spontaneous mammary tumor 
development, complete loss or insufficient production of 
adiponectin from adipocyte per se promotes mammary 
tumor onset and development [20, 21]. The present study 
demonstrates that adiponectin deficiency adversely affects 
lipid metabolism during tumorigenesis in MMTV-PyVT 
mice. Elevated circulating cholesterol levels promote 
mammary tumor development. Adiponectin inhibits 
cholesterol-stimulated proliferation of mammary tumor 
cells by reducing the low density lipoprotein receptor 
(LDLR) expression and cholesterol uptake. These actions 
of adiponectin are attributed in part to its role in regulating 
the autophagy process of the breast cancer cells.  
RESULTS
Accelerated tumor development in adiponectin 
deficient MMTV-PyVT mice is associated with 
elevated circulating and tumor cholesterol 
contents
Adiponectin deficient MMTV-PyVT mice were 
generated by backcrossing the original MMTV-PyVT mice 
Figure 1: Adiponectin deficiency accelerated breast cancer development and increased serum as well as tumor 
cholesterol levels in MMTV-PyVT mice. Female mice with genotypes of PyVT(+/-)ADN(+/+), PyVT(+/-)ADN(-/-), PyVT(-/-)
ADN(+/+) and PyVT(-/-)ADN(-/-) were fed with a standard chow from 3 weeks to 14 weeks. Tumor development (A) was monitored twice 
a week. Tumor sizes were measured using vernier calipers and tumor volume was calculated as described in Methods. Blood samples were 
collected from the tail vein of the mice once a week. Serum cholesterol (week 4-14) (B) and HDL/LDL-cholesterol contents (week 8, 10, 12 
and 14) (C) were detected from these serum samples. Lipids were extracted from tumor tissues of the PyVT(+/-)ADN(+/+) and PyVT(+/-)
ADN(-/-) mice at 10, 12 and 14 weeks. Total cholesterol levels (D) were detected from the tumor lipids. *, p < 0.05, **, p < 0.01, each group 
contained 10-16 mice, and results were presented as mean ± SD.
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with AKO mice in FVB/N background. The litters with 
control [PyVT(+/-)ADN(+/+)] or deficient adiponectin 
alleles [PyVT(+/-)ADN(-/-)] were used in the present 
study. Tumor development was monitored twice a week. 
From the age of 10 weeks, tumor growth was significantly 
accelerated in adiponectin deficient mice (Figure 1A). At 
the age of 14 weeks, the tumor size of PyVT(+/-)ADN(-
/-) mice was larger than PyVT(+/-)ADN(+/+) mice by 
~1.87 folds. At the time of sacrifice, the total wet weights 
of tumors were 3.1250 ± 1.4005 g and 1.7512 ± 0.4183 g, 
respectively, in the two groups of animals. Histological 
analysis revealed a markedly elevated necrotic area and 
stromal lymphocytic response in tumors derived from 
adiponectin deficient PyVT mice (Supplementary Figure 
1). 
Total serum cholesterol was measured using blood 
samples collected from mouse tail vein. The results 
demonstrated that from week 11, serum cholesterol 
levels in PyVT(+/-)ADN(+/+) mice were progressively 
decreased, whereas those in PyVT(+/-)ADN(-/-) mice 
were elevated (Figure 1B). At week 14, the difference 
between the two groups of mice was ~2.61 folds. Further 
analysis revealed that the high-density lipoprotein 
cholesterol (HDL-CHO) levels were reduced by ~35% 
and ~29% in 14-week old PyVT(+/-)ADN(+/+) and 
PyVT(+/-)ADN(-/-) mice, respectively, when compared to 
those at the age of 10 weeks. The low-density lipoprotein 
cholesterol (LDL-CHO) levels were significantly 
augmented only in PyVT(+/-)ADN(-/-) mice (Figure 1C). 
At week 14, the LDL-CHO level in PyVT(+/-)ADN(-
/-) mice was increased to nearly two folds of that in 
PyVT(+/-)ADN(+/+) mice (Figure 1C). These phenomena 
were not observed in mice carrying no PyVT transgene, 
irrespective of the adiponectin allele status (data not 
shown). Next, the cholesterol contents in tumors were 
evaluated. While at the age of 10 weeks, tumor cholesterol 
contents were not different between PyVT(+/-)ADN(+/+) 
and PyVT(+/-)ADN(-/-) mice, those in 12- and 14-week 
old PyVT(+/-)ADN(-/-) mice were significantly higher. 
The total amounts of cholesterol in tumor tissues collected 
Figure 2: Cholesterol promoted mammary tumor development and breast cancer cell proliferation. Female mice were 
fed with high fat high cholesterol (HFHC) diet from week 3 to week 14. Tumor development (A) was monitored twice a week, n = 15. 
Lipids were extracted from tumor tissues of the PyVT(+/-)ADN(+/+) and PyVT(+/-)ADN(-/-) mice at 14 weeks under HFHC diet. Total 
cholesterol levels (B) were detected from the tumor lipids, n = 9. Primary tumor cells were isolated from the PyVT(+/-)ADN(+/+) and 
PyVT(+/-)ADN(-/-) mice at 14 weeks under standard chow and cultured in serum free DMEM medium containing LDL-CHO (50 µg/ml) 
or HDL-CHO (50 µg/ml) for 24 hours and 48 hours. Cell proliferation was evaluated using [3H]-thymidine incorporation assay (C), n = 
4. [3H]-cholesterol (10 nM) uptake (D) was performed in these primary tumor cells treated with or without adiponectin (15 µg/ml) in the 
serum free DMEM medium for 15 min after fasting the cells for 24 hours, n = 6. *, p < 0.05; **, p < 0.01 and the mean value ± SD was 
presented.
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from PyVT(+/-)ADN(+/+) and PyVT(+/-)ADN(-/-) mice 
were 2.89 ± 0.46 mg and 6.50 ± 1.16 mg, respectively 
(Figure 1D).
Cholesterol treatment promoted mammary tumor 
development and breast cancer cell proliferation
The effect of high fat high cholesterol (HFHC) 
diet on tumor development was tested in PyVT(+/-)
ADN(+/+) and PyVT(+/-)ADN(-/-) mice. The diet 
treatment significantly reduced the tumor latency in 
PyVT(+/-)ADN(-/-) mice, for which the tumor onset was 
recorded at ~42 days, but did not significantly change that 
of PyVT(+/-)ADN(+/+) mice (~52 days). In both types 
of mice, tumor development was accelerated by HFHC 
diet (Figure 2A). Tumors collected at week 14 were much 
heavier in PyVT(+/-)ADN(-/-) mice (5.1418 ± 1.6334 g) 
compared to PyVT(+/-)ADN(+/+) mice (2.9562 ± 1.4290 
g). Again, the tumor cholesterol content in adiponectin 
deficient tumor was found to be much higher (15.75 ± 
4.25) than that (7.02 ± 1.02) of ADN(+/+) mice (Figure 
2B). 
The effect of cholesterol on the growth of primary 
tumor cells isolated from PyVT(+/-)ADN(+/+) and 
PyVT(+/-)ADN(-/-) mice was evaluated by [3H]-
thymidine incorporation assay (Figure 2C). The results 
showed an opposite outcome for LDL-CHO and HDL-
CHO treatments. After 48 hours of treatment, LDL-
CHO enhanced DNA incorporation by ~58% and ~78% 
in PyVT(+/-)ADN(+/+) and PyVT(+/-)ADN(-/-) tumor 
cells, respectively. By contrast, HDL-CHO suppressed 
cell growth by ~68% and ~76% in these two types of 
tumor cells (Figure 2C). The results revealed that [3H]-
cholesterol uptake was increased by ~24% in primary 
tumor cells derived from PyVT(+/-)ADN(-/-) mice when 
compared to that of PyVT(+/-)ADN(+/+) mice (Figure 
2D). Adiponectin treatment inhibited cholesterol uptake 
Figure 3: Adiponectin inhibited the uptake of cholesterol and LDL-cholesterol induced cell proliferation as well as 
β-catenin activity in breast cancer cells. A, [3H]-cholesterol (10 nM) uptake was performed in MDA-MB-231 human breast carcinoma 
cells treated with or without adiponectin (15 µg/ml) in the serum free DMEM medium for 15, 45 and 75 min after fasting the cells for 24 
hours, n = 12. B, MDA-MB-231 cells were treated with LDL-CHO (50 µg/ml) or mixtures of LDL-CHO (50 µg/ml) and adiponectin (15 
µg/ml) in serum free DMEM medium for 24, 48 and 72 hours. Cell proliferation was evaluated using [3H]-thymidine incorporation assay, 
n = 4. C, MDA-MB-231 breast cancer cells were treated with or without LDL-CHO (50 µg/ml) in the presence or absence of adiponectin 
(15 µg/ml) in serum free medium for 24 and 48 hours for nuclear β-catenin activity detection by TOPflash/FOPflash reporter assay, n = 4. 
*, p < 0.05; **, p < 0.01 and the mean value ± SD was presented.
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to a similar level in the two types of tumor cells. 
[3H]-cholesterol uptake in human breast carcinoma 
MDA-MB-231 cells was also investigated. Adiponectin 
treatment suppressed [3H]-cholesterol uptake and 
accumulation (Figure 3A). Moreover, in the presence of 
this protein, the proliferation-stimulatory effects of LDL-
CHO were significantly attenuated (Figure 3B). Chronic 
treatment of adiponectin could modulate beta-catenin 
activity in MDA-MB-231 cells [11]. Here, the results 
from TOPflash/FOPflash reporter assay demonstrated 
that cells cultured in LDL-CHO-containing media 
showed elevated nuclear beta-catenin activity, which 
was inhibited by adiponectin treatment (Figure 3C). 
Note that the hyperactivated beta-catenin signalling was 
Figure 4: Adiponetin inhibited LDLR expression. A, The amount of LDLR and actin were detected by Western blotting using the 
primary tumor cell lysates (left panel). The protein band intensities were quantified by densitometry. Fold changes were calculated and 
presented in the right panel, n = 4. B, mRNA of LDLR was detected by QPCR using RNAs derived from primary tumor cells, n = 6. C, 
MDA-MB-231 cells were treated with LDL-CHO (50 µg/ml) or the mixture of LDL-CHO (50 µg/ml) and adiponectin (15 µg/ml) in the 
serum free medium for 24 h. The expressions of LDLR were detected by Western blotting (upper panel) and immunocytochemistry staining 
(lower panel). D, MDA-MB-231 human breast cancer cells were pretreated with HDL-CHO (50 µg/ml) or LDL-CHO (50 µg/ml) in serum 
free medium for 24 hours. [3H]-cholesterol uptake was measured in these cells after treatment for 15 minutes, n = 4. *, p < 0.05; **, p < 
0.01, and the mean value ± SD was presented.
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also detected in cells derived from PyVT(+/-)ADN(-/-) 
mice (Supplementary Figure 2). The nuclear beta-catenin 
activity was ~2.52 folds higher in their cells compared 
with that in PyVT(+/-)ADN(+/+) tumor cells.
Low-density lipoprotein receptor (LDLR) 
expression is up-regulated in PyVT(+/-)ADN(-
/-) tumor cells and promotes breast cancer cell 
proliferation  
Since surface-expressed LDLR is responsible for 
cellular uptake of circulating LDL [26], Western blotting 
was performed to evaluate LDLR expression in primary 
tumor cells isolated from PyVT(+/-)ADN(+/+) and 
PyVT(+/-)ADN(-/-) mice. The total amount of LDLR in 
PyVT(+/-)ADN(-/-) tumor cells was significantly greater 
than that in PyVT(+/-)ADN(+/+) tumor cells (Figure 4A). 
The mRNA expression of Ldlr was not different between 
these two types of cells (Figure 4B). In MDA-MB-231 
cells, treatment with LDL-CHO induced a sharp elevation 
of the LDLR protein expression, whereas co-incubation 
with adiponectin blocked this effect (Figure 4C), and 
enhanced the cholesterol uptake (Figure 4D). 
To evaluate the effect of LDLR on breast cancer 
Figure 5: Overexpression of LDLR facilitated cell proliferation, increased cholesterol uptake and activated nuclear 
β-catenin activity in MDA-MB-231 human breast cancer cells. MDA-MB-231 human breast cancer cells were transfected 
with pcDNA, pcLDLR, control siRNA and LDLR siRNA with lipofectamine 2000. A, Overexpression of the LDLR was confirmed by 
Western blotting using anti-flag antibody. Downregulation of LDLR was detected by Western blotting using anti-LDLR antibody. B, Cell 
proliferation was evaluated at 24, 48 hours post-transfection using [3H]-thymidine incorporation assay, n = 6. C, Cells were transient 
transfected the LDLR siRNA and control siRNA for 24 hours and then treated with or without adiponectin (15 µg/ml) in 10% FBS DMEM 
for another 24 hours. Nuclear β-catenin activity was analyzed by TOPflash/FOPflash reporter assay, n = 4. Cells were transfected with 
pcDNA or pcLDLR for 48 hours for nuclear β-catenin activity analysis by TOPflash/FOPflash reporter assay (D), n = 4. E, [3H]-cholesterol 
uptake was detected in cells treated with or without adiponectin (15 µg/ml) in 10% FBS DMEM after transient transfection with pcLDLR 
or pcDNA (left panel) as well as LDLR siRNA and control siRNA (right panel), n = 6. *, p < 0.05; **, p < 0.01, and the mean value ± SD 
was presented.
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cell proliferation, MDA-MB-231 cells were transiently 
transfected with an expression vector encoding LDLR 
(pcLDLR) or the specific siRNA targeting LDLR (Figure 
5A). Compared to that of pcDNA-transfected cells, the 
proliferation rate in cells over-expressing LDLR was 
significantly higher and the cell number was increased 
by ~22% and ~48% after 24 and 48 hours of culture, 
respectively (Figure 5B). Down-regulation of LDLR 
expression by transfecting specific siRNA reduced the 
cell proliferation by ~20% and ~40% compared to cells 
transfected with control siRNA, at 24 and 48 hours, 
respectively. TOPflash/FOPflash reporter assay was 
performed to investigate the effect of LDLR on nuclear 
beta-catenin activity. Suppression of LDLR expression 
dramatically reduced the nuclear beta-catenin activity 
(Figure 5C). Conversely, overexpression of LDLR 
increased the nuclear activity of beta-catenin compared 
to MDA-MB-231 cells transfected with control vector 
(Figure 5D). [3H]-cholesterol uptake was increased in 
cells overexpressing LDLR and dramatically decreased 
by knocking down the expression of LDLR (Figure 
5E). Reducing LDLR expression by RNA interference 
attenuated cholesterol uptake by over 45% and abolished 
adiponectin-mediated inhibition of cholesterol uptake in 
MDA-MB-231 cells.
Adiponectin promotes LDLR degradation by 
increasing autophagic flux 
Both short (2 hours)- and long (24 hours)-term 
treatments with adiponectin reduced the protein abundance 
Figure 6: Adiponectin promoted trafficking of the LDLR to lysosome for degradation through increasing 
autophagosome formation. A, After fasting for 24   hours in serum free medium, cells were treated with or without adiponectin (15 
µg/ml) in the serum free DMEM medium for 2 and 24 hours. LDLR and actin were detected by Western blotting (left panel). Fold changes 
of the protein band intensities were quantified by densitometry (middle panel). mRNA of LDLR was detected by QPCR from MDA-
MB-231 cells treated either with or without adiponectin (right panel), n=6-8. B, MDA-MB-231 cells were grown on glass coverslips for 
immunocytochemistry staining. Arrow indicated the co-localization of LDLR and EEA1 as well as LDLR and LAMP1. C, Expression of 
LC3-I, LC3-II, Atg7 and Atg6 were analyzed in the primary tumor cell lysis by Western blotting, n = 3-5. D, MDA-MB-231 cells transiently 
transfected with GFP–LC3 were cultured at 37°C for 24 hours in 10% FBS DMEM medium with or without 15 µg/ml adiponectin and 
analyzed by immunocytochemistry staining. Arrow indicated the co-localization of LC3-II and LAMP1 in MDA-MB-231 cells treated with 
adiponectin. *, p < 0.05; **, p < 0.01 and the mean value ± SD was presented.
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of LDLR in MDA-MB-231 cells, but had no effect on 
the mRNA expressions (Figure 6A). Immunofluorescent 
staining demonstrated that adiponectin did not affect the 
trafficking of LDLR to early endosome, as indicated by 
the co-localization of LDLR and early endosome antigen 
(EEA)-1 in cells treated either with or without this protein. 
However, compared to vehicle treatment, it promoted the 
shuttling of LDLR into vesicles containing lysosomal-
associated membrane protein 1 (LAMP1) (Figure 6B).
Autophagy is a process to facilitate the degradation 
and recycle of intracellular proteins and organelles 
[27]. The first step of autophagy is the formation of 
autophagosome to sequester proteins or organelles 
into a double-membrane structure, which is then fused 
with lysosome to form autolysosome. An autophagy 
marker, ubiquitin-like protein Atg8 (known as LC3 in 
mammalian cells), was detected in primary tumor cells 
by Western blotting as two bands, LC3-I and LC3-II 
(Figure 6C). LC3-I is a cytosolic protein, whereas LC3-
II is a membrane-binding protein specifically associated 
with autophagosome and correlated with the extent of 
autophagosome formation [28]. Expression of LC3-II 
Figure 7: Adiponectin promoted LDLR degradation by increasing autophagy. A, MDA-MB-231 cells were treated with 
3-MA (8 mM) and/or adiponectin (15 µg/ml) in 10% FBS DMEM for 24 hours. Expression of LDLR was detected by Western blot (left 
panel). Fold changes of protein band intensities were quantified by densitometry (right panel), n = 3. B, MDA-MB-231 cells (5×106) 
were injected into the right thoracic mammary fat pad of 6-week-old female nude mice under anesthetic condition. The recombinant 
adenovirus [108 plaque-forming units (pfu)] that expressed adiponectin (Ad-ADN) or luciferase (Ad-LUC) was injected into the tumor of 
each mouse at the 14th day after initial implantation. All mice were sacrificed at 5 weeks after the initial implantation as described before 
[11]. Expression of LDLR was detected from the tumors by Western blot (left panel) and fold changes of protein band intensities were 
quantified by densitometry (right panel), n = 3-5. C, Expression of Atg6, Atg7 and LC3 were detected from the above tumors derived from 
nude mice by Western blot (left panel). Fold changes of protein band intensities were quantified by densitometry (right panel), n = 3-5. *, 
p < 0.05, **, p < 0.01 and the mean value ± SD was presented.
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was decreased in primary tumor cells from PyVT(+/-)
ADN(-/-) mice compared to those from PyVT(+/-)
ADN(+/+) mice (Figure 6C). Another two autophagy 
markers, autophagy-related protein 7 (Atg7) and Atg6 
(also known as Beclin-1), were also found to be decreased 
in PyVT(+/-)ADN(-/-) tumor cells. In MDA-MB-231 cells 
transiently transfected with a plasmid expressing GFP-
LC3, adiponectin treatment not only increased the number 
of puncta per cell, which represented the formation 
of autophagosomes, but also promoted the formation 
of autolysosomes as indicated by the large vacuoles 
containing both GFP-LC3 and LAMP1 (Figure 6D).
The specific inhibitor of autophagy, 3-methyladenine 
(3-MA), abolished adiponectin-induced reduction of LDLR 
in MDA-MB-231 cells in culture (Figure 7A). Moreover, 
in tumors collected from nude mice orthotopically 
implanted with MDA-MB-231 cells, adiponectin over-
expression reduced the LDLR protein expression (Figure 
7B). The stimulatory effects of adiponectin on autophagy 
markers, Atg7, Atg6 and LC3, could also be observed 
(Figure 7C).  
DISCUSSION
Evidences from epidemiologic studies have 
suggested that lower circulating adiponectin levels are 
associated with an increased risk of breast cancer in 
postmenopausal women [14]. The association can be 
found in women regardless of menopausal status [15, 29]. 
Moreover, tumors in women with low serum adiponectin 
levels are more likely to show biologically aggressive 
phenotypes and poor prognosis [15], such as large size of 
tumor and high histological grade. 
MMTV-polyomavirus middle T antigen (PyVT) 
transgenic mice, a well characterized breast cancer 
mouse model, were used in this study. These transgenic 
mice express high levels of the transforming oncogene 
PyVT under the control of the mouse mammary tumor 
virus promoter, which specifically directs expression to 
the mammary epithelium [30]. All female PyVT mice 
spontaneously develop multifocal adenocarcinomas in 
the mammary gland, with dysplastic foci occurring as 
early as age 7 weeks. Importantly, this mouse model 
recapitulates human breast cancer progression from early 
hyperplasia to malignant breast carcinoma [31, 32]. In 
the present study, the MMTV-PyVT transgenic mouse 
models under the condition of deficient adiponectin 
expression [ADN(-/-)] were established. Adiponectin 
deficiency accelerated the tumor development compared 
with control [ADN(+/+)] mice (Figure 1). Histological 
analysis of the tumor demonstrated markedly elevated 
tumor necrosis and stromal lymphocytic response in the 
tumors from ADN(-/-) mice (Supplementary Figure 1), 
which was consistent with our previous results found 
in PyVT transgenic mice with reduced adiponectin 
expression [20]. Adiponectin insufficiency might result 
in the development of a basal-like subtype tumor, which 
developed tumor more aggressively [20]. Breast cancers 
of the basal-like subtype comprise 19% of the tumors 
and have poor clinical outcomes, which likely reflect 
this subtype’s high proliferative capacity as well as the 
lack of directed therapies since basal-like tumors do not 
typically express ER or HER2 [33]. It was in accordance 
with the clinical evidence that adiponectin deficiency 
might result in the development of a tumor, which was 
more aggressive and had poor prognosis [14, 15]. Taken 
together, the above information suggests that PyVT mice 
with adiponectin deficiency are suitable animal models 
to study the mechanisms underlying the adiponectin 
insufficiency-induced breast carcinogenesis.
Epidemiological studies show that diet and obesity 
represent significant risk factors for cancer development 
[5, 6]. In this study, high fat high cholesterol diet (HFHC) 
diets reduced the tumor latency in PyVT(+/-)ADN(-/-) 
mice. In addition, HFHC promoted tumor development of 
both kinds of PyVT mice and increased the necrosis in 
tumors compared with the standard chow group. It was 
consistent with the results from other groups that obesity 
induced by high fat diet significantly accelerated tumor 
growth and shorten tumor latency in tumor-bearing mice 
[34, 35].
It has been known for about a century that 
cholesterol and other lipids accumulate in solid tumors 
[36]. Experimental evidence showed that cholesterol, 
cholesterol oxidation products (Oxysterols) and cholesterol 
precursor (mevalonate) enhanced tumorigenesis [37, 
38]. In addition, 3-hydroxy-3-methylglutaryl-coenzyme 
A (HMG-CoA) inhibitors exhibited pleiotropic 
antineoplastic effects in a variety of tumors [39]. In our 
study, total plasma cholesterol levels were reduced in 
the PyVT(+/-)ADN(+/+) mice during tumorigenesis 
(Figure 1B), which was similar with the clinical studies. 
Evidence from epidemiologic and experimental studies 
have documented an association between low circulating 
cholesterol and high overall cancer incidence and mortality 
in prostate cancer [40], breast cancer [37] and several 
other cancers [41, 42]. This correlation might attribute to 
the increased utilization of cholesterol by tumors. Our in 
vitro studies showed that LDL-CHO promoted nuclear 
beta-catenin activity and facilitated proliferation of breast 
cancer cells or primary cancer cells isolated from the 
PyVT mice (Figure 3). Adiponectin deficiency elevated 
plasma cholesterol and LDL-CHO levels (Figure 1), which 
could further enhance the breast cancer development and 
activate AKT/GSK3beta/beta-catenin signalling pathway, 
resulting in accelerating tumorigenesis. This was further 
corroborated by the cholesterol contents in the tumors 
showing higher cholesterol contents in tumors from 
PyVT(+/-)ADN(-/-) mice than those in the PyVT(+/-)
ADN(+/+) mice (Figure 1&2). 
Increasing cholesterol levels in tumor tissues 
have been attributed to multiple mechanisms, including 
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increased absorption from the circulation, loss of feedback 
regulation through downregulation of low-density 
lipoprotein receptors, and upregulation of components 
of the mevalonate pathway, particularly HMG-CoA 
reductase [43, 44]. Cells, as in other tissues, synthesize 
cholesterol endogenously via the mevalonate pathway. 
Cellular cholesterol also derives from absorption from 
circulating lipoproteins. Control of cellular cholesterol 
content is a balance between metabolic processes intrinsic 
to the cells and the regulation of cholesterol distribution 
by the organism. Low-density lipoprotein receptor 
(LDLR), a plasma cholesterol homeostasis regulator, 
plays an important role in carcinogenesis. This pathway 
provides cells with essential fatty acids for prostaglandin 
E2 (PGE2) synthesis. PGE2 synthesis in prostate cancer 
cells was significantly increased in response to LDL. 
Over-production of LDLR is an important mechanism 
in cancer cells for obtaining more essential fatty acids 
through LDLR endocytosis, allowing increased synthesis 
of prostaglandins, which subsequently stimulate cell 
growth. Over-expression of LDLR occurs in many types 
of malignancies and is related to the rapid proliferation 
of tumors. In adenomatous polyposis coli (Apc)-deficient 
Min mice, LDLR was overexpressed in the epithelia of the 
upper part of polyps where lipid droplets were observed. 
The expression levels of Ldlr mRNA in the intestinal 
polyps of Min mice were approximately three times 
higher compared to those in the non-tumor parts [45]. The 
expression level of LDLR was up-regulated in human lung 
adenocarcinoma A549 cells [46] and colorectal carcinoma 
cells [47]. In our study over-expression of LDLR 
facilitated proliferation of breast cancer cells (Figure 5B) 
and increased stability and nuclear beta-catenin activity 
(Figure 5D) as well as elevated cholesterol uptake (Figure 
5E), thereby promoting tumor development. By contrast, 
down-regulated LDLR attenuated cell proliferation 
(Figure 5B) and nuclear beta-catenin activity (Figure 
5C) as well as inhibited cholesterol uptake (Figure 5E) in 
MDA-MB-231 human breast cancer cells.
An interesting phenomenon in this study is that 
adiponectin deficiency increased total cholesterol and 
LDL-CHO levels compared with the ADN(+/+) mice 
during tumor development (Figure 1), which might 
facilitate the uptake and utilization of cholesterol by 
tumors, accelerate the tumor development and exacerbate 
their aggressiveness. There are discrepancies in the two 
kinds of mice during tumor development. In ADN(+/+) 
mice at the later stage of tumor development, adiponectin 
level decreased and cholesterol level also decreased; 
while in ADN(-/-) mice, no adiponectin expression is 
associated with increased cholesterol levels. The effects 
of adiponectin on lipid metabolism could explain these 
phenomena. Low serum adiponectin is commonly 
associated with dyslipidemia characterized by an increase 
in plasma levels of triglyceride (TG), LDL-CHO, 
apolipoprotein B-48, apolipoprotein C-III, chylomicrons 
and liver fat content, as well as a decrease in whole-
body fat oxidation and HDL-CHO, independent of age, 
sex, body mass index, and diabetes [48, 49]. Here, the 
altered lipid metabolism was further corroborated by the 
lipid contents in the livers (Supplementary Figure 3). 
Adiponectin deficiency increased the fat accumulation in 
liver. Adiponectin influences plasma lipoprotein levels by 
altering the levels and activity of key enzymes (lipoprotein 
lipase and hepatic lipase) responsible for the catabolism 
of TG-rich lipoproteins and HDL [50]. Thus, the elevated 
TG, cholesterol and LDL-CHO levels in PyVT(+/-)ADN(-
/-) mice might partly be the consequence of altered lipid 
metabolism in liver under adiponectin deficient condition 
during tumor development.
Autophagy plays important role both in 
carcinogenesis and lipid metabolism. It suppresses 
tumorigenesis at the early stage, while promotes tumor 
progression at the later stage of tumor development [51]. 
Moreover, autophagy regulates lipid content. Inhibition 
of autophagy in cultured hepatocytes and mouse liver 
increases triglyceride storage in lipid droplets [52]. In 
our study, adiponectin increased autophagy both in vitro 
(Figure 6) and in vivo (Figure 7C). Adiponectin decreased 
LDLR expression (Figure 4A, 6A & 7B) and trafficked 
LDLR to lysosome for degradation (Figure 6B) through 
autophagy (Figure 7A). Increasing levels of TG and 
cholesterol in livers and serum (Supplementary Figure 3 
& Figure 1B) from PyVT(+/-)ADN(-/-) mice compared 
to those in the PyVT(+/-)ADN(+/+) mice might partially 
attributed to the inhibition effects of autophagy in 
adiponectin knockout condition. 
In summary adiponectin deficiency increased 
obesity-associated breast malignancies in a MMTV-PyVT 
transgenic mouse model. Adiponectin knockout altered the 
lipid metabolism in the liver, by secretion of more TG, 
LDL-CHO and cholesterol into the plasma, which further 
enhance the breast cancer development. In the adiponectin 
wild type PyVT mice, adiponectin had the direct actions 
to the cancer cells to attenuate cell proliferation as well as 
indirect mechanisms regulating systemic lipid metabolism 
and inhibition of cholesterol accumulation in the tumor 
by autophagy-mediated down-regulation of LDLR. 




Anti-β-catenin, anti-phosphorylated (Ser473) AKT, 
and anti-phosphorylated (Ser9) glycogen synthase kinase-
3β (GSK-3β), Atg7, Atg6, LC3 antibodies were obtained 
from Cell Signaling (Beverly, MA). Goat anti-β-actin 
was obtained from Santa Cruz Biotechnology (Santa 
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Cruz, CA). Anti-LDLR and anti-LAMP1 antibodies 
were obtained from Abcam (Cambridge, MA). Anti-
EEA1 antibody was obtained from BD Tranduction 
Laboratories. The MDA-MB-231 cells were obtained from 
the American Type Culture Collection (Manassas, VA). 
ImProm-IITM Reverse Transcription System and Bright-
GloTM luciferase assay system were from Promega 
(Madison, WI). TOP/FOPflash (T-cell factor-lymphoid 
enhancer factor-1 (TCF-LEF) reporter plasmid) was from 
Upstate (Lake Placid, NY). pcDNA 3.1 (+) and pcLDLR 
were from Invitrogen (Carlsbad, CA) and Fulengen 
(Guangzhou, P.R. China), respectively. pLC3B-GFP 
vector was supplied by Dr. NS Wong from the University 
of Hong Kong. Recombinant adiponectin was produced 
from Escherichia coli as previously described [11]. Low-
density-lipoprotein (LDL), High-density-lipoprotein 
(HDL) and 3-Methyladenine (3-MA) were obtained from 
Sigma (Saint Louis, MO). [3H]-cholesterol solution and 
[3H]-thymidine solution were from Amersham Biosciences 
(Uppsala, Sweden).
Establishment of the MMTV-PyVT transgenic 
mice without adiponectin expression
FVB/N-Tg(MMTV-PyVT)634Mul/J transgenic 
mice were obtained from the Jackson Laboratory (Bar 
Harbor, Maine). MMTV-PyVT mice with adiponectin 
insufficient [PyVT(+/-)ADN(+/-)] were established as 
described previously [20]. A FVB/N line of adiponectin 
insufficient mice [PyVT(+/-)ADN(+/-)] was established 
by backcrossing this female adiponectin insufficient 
mice [PyVT(-/-)ADN(+/-)] with male PyVT(+/-) mice 
from Jackson Laboratory (FVB/N background) for at 
least 18 generations. Since adiponectin knockout PyVT 
mice [PyVT(+/-)ADN(-/-)] could not be obtained by 
crossbreeding male PyVT(+/-)ADN(+/-) with female 
PyVT(-/-)ADN(+/-) [20], the FVB/N line of adiponectin 
knockout mice [PyVT(-/-)ADN(-/-)] were established by 
crossing the littermates from the male PyVT(-/-)ADN(+/-
) with female PyVT(-/-)ADN(+/-). PyVT(+/-)ADN(-/-) 
mice were generated from male PyVT(+/-)ADN(+/-) 
crossed with female PyVT(-/-)ADN(-/-). Female mice 
were used for all experiments in the present study. Tumor 
development was closely monitored twice a week. 
Tumor latency was recorded as the age of mice when 
palpable tumors were first detected in at least one of the 
ten mammary fat pads. Tumor size was measured using 
a vernier caliper and tumor volume was calculated using 
the formula [sagittal dimension (mm) × cross dimension 
(mm)2] / 2 and expressed in mm3. Serum total cholesterol, 
LDL-cholesterol and HDL-cholesterol were examined 
according to the manual of individual kits from Standbio 
Laboratory (TX, USA). All animal experimental protocols 
were approved by the Animal Ethics Committee at the 
University of Hong Kong and their care was in accord 
with the institution guidelines.
Isolation of primary mammary tumor cells
Primary mammary tumor cells were isolated as 
described previously with slight modifications [23]. Fresh 
tumors were collected aseptically from anesthetized PyVT 
mice, mechanically minced, suspended in serum-free high 
glucose DMEM medium and passed through 40 μm sterile 
nylon cell strainers (BD Falcon). Tumor cell suspension 
was further disintegrated by serial passaging through a 10 
ml syringe without a needle. After a brief centrifugation 
at 1,000 rpm for 5 minutes at room temperature for 
the removal of cell debris and the low-density stromal 
cells, pellets predominantly containing tumor cells were 
suspended in serum free high glucose DMEM medium for 
viable cell counting using 0.4% trypan blue. For in vitro 
cell culture, isolated primary tumor cells were suspended 
with high glucose DMEM medium with 10% FBS, 
cultured and attached overnight in a 37 oC incubator with 
humidified atmosphere of 5% CO2. The culture medium 
was then changed every other day. Attached cells were 
subjected to other in vitro assays.
[3H]-thymine incorporation assay for cell 
proliferation measurement
Cells were seeded at a density of 5000 per well in 
96-well plates. After starving in DMEM for 24 hours, cells 
were treated at different conditions as indicated. One μCi/
ml of [3H]-thymidine was added into each well for the last 
6 hours of treatment. At the end of the experiment, the 
culture media were removed and cells were washed with 
cold PBS. DNA was precipitated with 0.5% trichloroacetic 
acid for 30 minutes. Air-dried precipitates were then 
solubilized with 0.2 M NaOH, neutralized with 0.2 M 
HCl, and incorporated [3H]-thymidine was qualified with 
a liquid scintillation counter (Backman LS6500).
Lipid extraction from tissues
Tissue lipids were isolated as described with slight 
modifications [24]. Total lipids from 100 mg tumor 
tissues were extracted with an organic solvent mixture 
of chloroform and methanol (vol:vol 2:1). Tissue debris 
or insoluble protein was pelleted by centrifugation at 
14,000 rpm at 4 °C for 5 minutes. Soluble protein was 
separated by water extraction. Samples were centrifuged 
at 12,000 × g at 4 °C for 5 minutes to separate lipid with 
soluble proteins. The lower layer containing lipid was 
aspirated and dried under nitrogen gas flow. Lipids were 
emulsified by sonication in a PBS buffer containing 0.1% 
Triton X-100. Cholesterol was examined according to the 




MDA-MB-231 human breast cancer cells were 
trypsinized and subcultured onto the coverslips. After 
various treatments, the cells were fixed with 4% 
paraformaldehyde (PFA) in PBS for 15 minutes and 
permeabilized in PBS with 0.2% Triton X-100 or 0.2% 
Tween 20 for 5 minutes at room temperature. After three 
washing steps in PBS, cells were incubated with blocking 
buffer (3% BSA in PBS) for 1 hour at room temperature. 
Then cells were incubated with a primary antibody 
diluted in PBS containing 1% BSA in a humid chamber 
at 4oC overnight. After washing another three times with 
PBS, the cells were incubated with the goat anti-rabbit 
Alexa Fluor 488 and goat anti-mouse Alexa Fluor 594 
secondary antibodies (Invitrogen, California, USA) in 
PBS with 1% BSA in the dark at room temperature for 1 
hour. The coverslips were then washed three times with 
PBS and mounted with ProLong Gold Anti-fade Reagent 
(Invitrogen, California, USA) for durable visualization. 
The coverslips were then observed under a fluorescence 
microscope (Leica Microsystems, Bensheim, Germany), 
and the images were captured using AxioVision Imaging 
Plus software (Carl Zeiss, Inc., International).
TOPflash/FOPflash β-catenin/T-cell factor-
lymphoid enhancer factor (TCF-LEF) reporter 
assay
Nuclear activities of endogenous β-catenin were 
analyzed by the TOPflash/FOPflash reporter system 
(Upstate, Charlottesville, VA) as described previously 
[11]. Cells grown in 24-well plates under different 
treatments were transfected with either the TOPflash or 
FOPflash plasmid using lipofectamine reagent (Invitrogen, 
Carlsbad, CA). To normalize the transfection efficiency 
in the reporter assays, cells were co-transfected with 
pRL-TK plasmid, which contains a functional Renilla 
luciferase gene cloned downstream of a herpes simplex 
virus thymidine kinase promoter (Promega, Madison, WI). 
At the point of harvest, cells were washed with PBS and 
lysed with the reporter lysis buffer (Promega). Cell lysates 
were collected and luciferase activity was measured using 
Bright-GloTM Luciferase Assay System (Promega, 
Madison, WI) on Lumat LB9507 (Berthold Technologies, 
Bad Wildbad, Germany) and normalized against control 
Renilla luciferase signal. Luciferase activity was 
calculated against the negative control signal and fold 
changes were compared among groups in separate assays.
[3H]-cholesterol uptake
Cells were seeded at a density of 2×104 per well 
in 24-well plates. After starving in DMEM for 24 hours, 
cells were treated at different conditions as indicated. 
Ten nanomole [3H]-cholesterol (Amersham Biosciences, 
Uppsala, Sweden) was added in serum free DMEM 
to the cells for 15, 45 and 75 minutes. Prior to isotope 
addition, the original [3H]-cholesterol/toluene suspension 
was dried down under N2 and resuspended in the same 
volume of 100% ethanol as indicated [25]. By the end 
of the experiment, the culture media were removed and 
cells were washed three times with cold PBS. Cells were 
then lysed with 0.2 M NaOH, neutralized with 0.2 M HCl, 
and subjected to liquid scintillation counting to determine 
cellular cholesterol uptake with a liquid scintillation 
counter (Backman LS6500).
Quantitative RT-PCR
Total RNA was isolated and used for the synthesis 
of cDNA. Quantitative RT-PCR was performed using 
SYBR® Green real-time PCR reagents were from 
Qiagen (Hilden, Germany). The reactions were carried 
out on a 7000 Sequence Detection System (Applied 
Biosystems, Foster City, CA). Quantification was 
achieved using Ct values that were normalized with 
GAPDH as internal control. The primers for mouse 
Ldlr were (F) 5’-TGACTCAGACgAACAAGGCTG-3’ 
and (R) 5’-ATCTAGGCAATCTCGGTCTCC-3’. 
The primers for mouse Gapdh were (F) 
5’-CAGAACATCATCCCTGCATC-3’ and 
(R) 5’-CTGCTTCACCACCTTCTTGA-3’. 
The primers for human LDLR were (F) 
5’-GCTTGTCTGTCACCTGCAAA-3’ and 
(R) 5’-AACTGCCGAGAGATGCACTT-3’. 
The primers for human ACTIN were (F) 
5’-TGACCCAGATCATGTTTGAGA-3’ and (R) 
5’-AGTCCATCACGATGCCAGT-3’.
Western blotting
Total cell lysates were separated by SDS-PAGE, 
transferred to polyvinylidene difluoride membranes, and 
then probed with various primary antibodies to determine 
the expression of the signaling proteins, including 
phosphorylated AKT, GSK-3β, total β-catenin, actin and 
autophagy markers in MDA-MB-231 cells and primary 
tumor cells. The antibody-antigen complexes were 
detected using an enhanced chemiluminescence kit from 
GE Healthcare (Uppsala, Sweden).
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Statistics
All the experiments were repeated for at least 
three times. For Western blotting, representative images 
were shown. Results were presented as mean ± standard 
deviation (SD). Statistical analysis of difference between 
two groups was performed using Student’s t-test. A 
p-value of less than 0.05 represents a significant difference 
in all statistical comparisons (*, p < 0.05; **, p < 0.01).
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